pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$FATEFATE THERAPEUTICS INC

$FATE
San Diego, CA, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
8
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(8)

pipeline depth8 products
Preclinical: 3Phase 1: 5
3Preclinical5Phase 1
Phase 1
FT-522
B-Cell Non-Hodgkin Lymphoma
Phase 1
FT-576
Refractory Multiple Myeloma
Phase 1
FT-819
Idiopathic Inflammatory Myopathy (IIM)
Phase 1
FT-825
Colorectal Cancer
Phase 1
FT-836
Breast Cancer
Preclinical
FT-839
Hematological Tumor
Preclinical
FT-8XX
Unspecified Cancer
Preclinical
Undisclosed
Solid Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritisrecruitingn=53
  • phase1FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumorsrecruitingn=113
  • phase1FT819 in Subjects With B-cell Malignanciesactive not recruitingn=54
  • phase1A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseaserecruitingn=244
  • phase1FT576 in Subjects With Multiple Myelomacompletedn=31
  • phase1FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumorsrecruitingn=351
  • phase1FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)completedn=20
  • phase1FT516 in Subjects With Advanced Hematologic Malignanciesterminatedn=72
🐶 Hiring Signal
No open roles indexed yet — view FATE THERAPEUTICS INC jobs →

News

  • This week in charts: Brain drugs are back on venture capitalists’ minds
    Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
    biopharma_dive · 7d ago
  • Despite midterm losses, RFK Jr. is bullish on MAHA's future
    Rumors and speculation have swirled all year about the fate of HHS Secretary Robert F. Kennedy Jr., the political face of the Make America Healthy Again movement. But after a bruising midterm elect…
    endpoints · 10d ago
  • Democrats’ midterm victory, and a questionable fertility procedure
    How will the midterm results affect drug pricing policy? And why are women traveling to fertility clinics abroad? Find out on the new episode of "The Readout LOUD" podcast.
    stat · 14d ago
  • STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
    Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.
    stat · 15d ago
  • STAT+: Where does MAHA go from here? 3 possible futures
    Republican losses leave Robert F. Kennedy Jr.’s MAHA movement with three possible futures.
    stat · 16d ago
  • Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
    Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather…
    biospace · 16d ago
  • STAT+: Kennedy’s closing arguments for the 2026 midterms: Fraud, vaccines, and MAHA
    RFK Jr. is making his pitch ahead of a midterm election that could shape the fate of his MAHA movement.
    stat · 22d ago
  • ‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 days
    Chicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as four days.
    fiercebiotech · 24d ago
  • From cells to organoids: Cytokines that shape 3D culture
    High-quality cytokines for organoid growth, differentiation, and expansion.
    biospace · 1mo ago
  • The Trump administration is doubling down on health care fraud investigations
    At the STAT Summit, the Department of Justice offered up a warning for health care executives: Don’t be another Theranos.
    stat · 1mo ago
view all news mentions →
identifiers
ticker
$FATE
SEC CIK
0001434316
country
US
source
sec_tickers
top tags
Oncology8Immunology3Colorectal Cancer2NSCLC2Breast Cancer1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?